Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration

Hae Min Kang, Hee Jung Kwon, Jeong Ho Yi, Christopher Seungkyu Lee, Sungchul Lee

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Purpose To investigate the prognostic implication of subfoveal choroidal thickness on treatment outcome after intravitreal ranibizumab injections for typical exudative age-related macular degeneration (AMD). Design Retrospective study. Methods A total of 40 eyes of 37 patients who completed 6-month follow-up were analyzed. Patients' data were retrieved from medical records including best-corrected visual acuity (BCVA). Subfoveal choroidal thickness at baseline, 3 months, and 6 months was measured by enhanced depth imaging optical coherence tomography and adjusted for age and sex before statistical analysis. Treatment response was after 3 monthly intravitreal ranibizumab injections. Responders (responder group) were defined as a 100 μm or more decrease or complete resolution of subretinal fluid, whereas nonresponders (nonresponder group) were defined as changes less than 100 μm or more than 100 μm increase of subretinal fluid by optical coherence tomography. Results Mean age at diagnosis was 72.1 ± 8.1 years, and 22 eyes (55.0%) were responders. The responder group had thicker subfoveal choroid (257.2 ± 108.3 μm) and smaller lesions (1.3 ± 0.8 μm) at baseline than the nonresponder group (167.1 ± 62.4 μm, P =.003; and 2.0 ± 1.0 μm, P =.008). The responder group showed significantly better BCVA and thicker subfoveal choroid than the nonresponder group at 3 months (P =.002 and P =.023) and 6 months (P =.004 and P =.031). Stepwise and binary regression analysis demonstrated that subfoveal choroidal thickness was significantly correlated with visual outcome (B = -0.002, P =.003) and treatment response (B = 8.136, P =.018). Conclusion Subfoveal choroidal thickness may be a predictive factor for visual outcome and treatment response in typical exudative AMD after intravitreal ranibizumab injections.

Original languageEnglish
JournalAmerican Journal of Ophthalmology
Volume157
Issue number5
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Intravitreal Injections
Macular Degeneration
Subretinal Fluid
Choroid
Optical Coherence Tomography
Visual Acuity
Medical Records
Retrospective Studies
Regression Analysis
Therapeutics
Ranibizumab

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

@article{1218cb028bd2452391cad8808a15267b,
title = "Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration",
abstract = "Purpose To investigate the prognostic implication of subfoveal choroidal thickness on treatment outcome after intravitreal ranibizumab injections for typical exudative age-related macular degeneration (AMD). Design Retrospective study. Methods A total of 40 eyes of 37 patients who completed 6-month follow-up were analyzed. Patients' data were retrieved from medical records including best-corrected visual acuity (BCVA). Subfoveal choroidal thickness at baseline, 3 months, and 6 months was measured by enhanced depth imaging optical coherence tomography and adjusted for age and sex before statistical analysis. Treatment response was after 3 monthly intravitreal ranibizumab injections. Responders (responder group) were defined as a 100 μm or more decrease or complete resolution of subretinal fluid, whereas nonresponders (nonresponder group) were defined as changes less than 100 μm or more than 100 μm increase of subretinal fluid by optical coherence tomography. Results Mean age at diagnosis was 72.1 ± 8.1 years, and 22 eyes (55.0{\%}) were responders. The responder group had thicker subfoveal choroid (257.2 ± 108.3 μm) and smaller lesions (1.3 ± 0.8 μm) at baseline than the nonresponder group (167.1 ± 62.4 μm, P =.003; and 2.0 ± 1.0 μm, P =.008). The responder group showed significantly better BCVA and thicker subfoveal choroid than the nonresponder group at 3 months (P =.002 and P =.023) and 6 months (P =.004 and P =.031). Stepwise and binary regression analysis demonstrated that subfoveal choroidal thickness was significantly correlated with visual outcome (B = -0.002, P =.003) and treatment response (B = 8.136, P =.018). Conclusion Subfoveal choroidal thickness may be a predictive factor for visual outcome and treatment response in typical exudative AMD after intravitreal ranibizumab injections.",
author = "Kang, {Hae Min} and Kwon, {Hee Jung} and Yi, {Jeong Ho} and Lee, {Christopher Seungkyu} and Sungchul Lee",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.ajo.2014.01.019",
language = "English",
volume = "157",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "5",

}

Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration. / Kang, Hae Min; Kwon, Hee Jung; Yi, Jeong Ho; Lee, Christopher Seungkyu; Lee, Sungchul.

In: American Journal of Ophthalmology, Vol. 157, No. 5, 01.01.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration

AU - Kang, Hae Min

AU - Kwon, Hee Jung

AU - Yi, Jeong Ho

AU - Lee, Christopher Seungkyu

AU - Lee, Sungchul

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose To investigate the prognostic implication of subfoveal choroidal thickness on treatment outcome after intravitreal ranibizumab injections for typical exudative age-related macular degeneration (AMD). Design Retrospective study. Methods A total of 40 eyes of 37 patients who completed 6-month follow-up were analyzed. Patients' data were retrieved from medical records including best-corrected visual acuity (BCVA). Subfoveal choroidal thickness at baseline, 3 months, and 6 months was measured by enhanced depth imaging optical coherence tomography and adjusted for age and sex before statistical analysis. Treatment response was after 3 monthly intravitreal ranibizumab injections. Responders (responder group) were defined as a 100 μm or more decrease or complete resolution of subretinal fluid, whereas nonresponders (nonresponder group) were defined as changes less than 100 μm or more than 100 μm increase of subretinal fluid by optical coherence tomography. Results Mean age at diagnosis was 72.1 ± 8.1 years, and 22 eyes (55.0%) were responders. The responder group had thicker subfoveal choroid (257.2 ± 108.3 μm) and smaller lesions (1.3 ± 0.8 μm) at baseline than the nonresponder group (167.1 ± 62.4 μm, P =.003; and 2.0 ± 1.0 μm, P =.008). The responder group showed significantly better BCVA and thicker subfoveal choroid than the nonresponder group at 3 months (P =.002 and P =.023) and 6 months (P =.004 and P =.031). Stepwise and binary regression analysis demonstrated that subfoveal choroidal thickness was significantly correlated with visual outcome (B = -0.002, P =.003) and treatment response (B = 8.136, P =.018). Conclusion Subfoveal choroidal thickness may be a predictive factor for visual outcome and treatment response in typical exudative AMD after intravitreal ranibizumab injections.

AB - Purpose To investigate the prognostic implication of subfoveal choroidal thickness on treatment outcome after intravitreal ranibizumab injections for typical exudative age-related macular degeneration (AMD). Design Retrospective study. Methods A total of 40 eyes of 37 patients who completed 6-month follow-up were analyzed. Patients' data were retrieved from medical records including best-corrected visual acuity (BCVA). Subfoveal choroidal thickness at baseline, 3 months, and 6 months was measured by enhanced depth imaging optical coherence tomography and adjusted for age and sex before statistical analysis. Treatment response was after 3 monthly intravitreal ranibizumab injections. Responders (responder group) were defined as a 100 μm or more decrease or complete resolution of subretinal fluid, whereas nonresponders (nonresponder group) were defined as changes less than 100 μm or more than 100 μm increase of subretinal fluid by optical coherence tomography. Results Mean age at diagnosis was 72.1 ± 8.1 years, and 22 eyes (55.0%) were responders. The responder group had thicker subfoveal choroid (257.2 ± 108.3 μm) and smaller lesions (1.3 ± 0.8 μm) at baseline than the nonresponder group (167.1 ± 62.4 μm, P =.003; and 2.0 ± 1.0 μm, P =.008). The responder group showed significantly better BCVA and thicker subfoveal choroid than the nonresponder group at 3 months (P =.002 and P =.023) and 6 months (P =.004 and P =.031). Stepwise and binary regression analysis demonstrated that subfoveal choroidal thickness was significantly correlated with visual outcome (B = -0.002, P =.003) and treatment response (B = 8.136, P =.018). Conclusion Subfoveal choroidal thickness may be a predictive factor for visual outcome and treatment response in typical exudative AMD after intravitreal ranibizumab injections.

UR - http://www.scopus.com/inward/record.url?scp=84898925452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898925452&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2014.01.019

DO - 10.1016/j.ajo.2014.01.019

M3 - Article

VL - 157

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 5

ER -